| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target of Suloctidil HCl is the Na⁺/K⁺ ATPase, a membrane-bound ion pump responsible for maintaining electrochemical gradients. It acts as an inhibitor of Na⁺/K⁺ ATPase activity and modulates membrane fluidity. By inhibiting this pump, it affects vascular smooth muscle tone and peripheral blood flow. It is a peripheral vasodilator that was formerly used for vascular disorders.
|
|---|---|
| ln Vitro |
In vitro, Suloctidil HCl is a peripheral vascular dilator and Na⁺/K⁺ ATPase inhibitor. It modulates membrane fluidity in various cell types. Specific IC50 values for Na⁺/K⁺ ATPase inhibition are reported in the literature. It is used as a reference compound for studying vascular pharmacology. It is typically tested at concentrations ranging from 1 to 100 µM.
|
| ln Vivo |
In vivo, Suloctidil HCl was formerly used in the management of peripheral and cerebral vascular disorders. It is hepatotoxic and fatalities have occurred, leading to its withdrawal. Specific published in vivo efficacy data, including dosing regimens and clinical outcomes, are reported in clinical literature. It is primarily used as a research tool for studying Na⁺/K⁺ ATPase inhibition and vascular pharmacology.
|
| Enzyme Assay |
The Na⁺/K⁺ ATPase inhibition assay uses purified enzyme from kidney or brain tissue or recombinant enzyme expressed in cells. The enzyme is incubated with ATP and varying concentrations of Suloctidil HCl in reaction buffer. ATP hydrolysis is measured by quantifying inorganic phosphate release using a colorimetric assay. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For cell-based assays, vascular smooth muscle cells or endothelial cells are treated with Suloctidil HCl. Na⁺/K⁺ ATPase activity is measured in cell lysates using ATP as substrate. Membrane fluidity is assessed using fluorescence polarization with DPH or TMA-DPH probes. Cell viability is evaluated using MTT or LDH release assays.
|
| Animal Protocol |
In vivo studies with Suloctidil HCl employed rodent models for vascular assessment. The compound is dissolved in saline and administered intraperitoneally or orally. Key readouts include blood pressure, peripheral blood flow, and Na⁺/K⁺ ATPase activity in tissues. Due to its hepatotoxicity, in vivo studies are conducted with appropriate safety precautions.
|
| References | |
| Additional Infomation |
peripheral vasodilator previously used to treat peripheral and cerebrovascular diseases. It is hepatotoxic and has been the cause of death in some cases. (Excerpt from Martindale Pharmacopoeia, 30th edition, page 1312)
|
| Molecular Formula |
C20H36CLNOS
|
|---|---|
| Molecular Weight |
374.0239
|
| Exact Mass |
373.221
|
| CAS # |
54767-71-4
|
| Related CAS # |
54767-75-8 (Parent)
|
| PubChem CID |
44153242
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.752
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
24
|
| Complexity |
277
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCNC(C)C(C1=CC=C(C=C1)SC(C)C)O.Cl
|
| InChi Key |
JRJJHIUHSILDOH-ZHXLSBKVSA-N
|
| InChi Code |
InChI=1S/C20H35NOS.ClH/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3;/h11-14,16-17,20-22H,5-10,15H2,1-4H3;1H/t17-,20-;/m0./s1
|
| Chemical Name |
(1R,2S)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6737 mL | 13.3683 mL | 26.7365 mL | |
| 5 mM | 0.5347 mL | 2.6737 mL | 5.3473 mL | |
| 10 mM | 0.2674 mL | 1.3368 mL | 2.6737 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
